Cargando…

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia

The administration of aripiprazole (ARI), a dopamine partial agonist, could provoke abrupt psychotic worsening in patients with schizophrenia. We explored the relationship between this psychotic worsening and dopamine supersensitivity psychosis (DSP), which is a clinically vulnerable state. We condu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takase, Masayuki, Kanahara, Nobuhisa, Oda, Yasunori, Kimura, Hiroshi, Watanabe, Hiroyuki, Iyo, Masaomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363127/ https://www.ncbi.nlm.nih.gov/pubmed/25735995 http://dx.doi.org/10.1177/0269881115570083

Ejemplares similares

Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis
por: Tadokoro, Shigenori, et al.
Publicado: (2012)

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia
por: Kanahara, Nobuhisa, et al.
Publicado: (2021)

Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases
por: Kanahara, Nobuhisa, et al.
Publicado: (2023)

Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report
por: Tadokoro, Shigenori, et al.
Publicado: (2017)

Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis
por: Kobayashi, Remiko, et al.
Publicado: (2020)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2012)

First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort
por: Kanahara, Nobuhisa, et al.
Publicado: (2018)

Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine
por: Takao, Nagara, et al.
Publicado: (2021)

Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia
por: Ma, Chia-Hao, et al.
Publicado: (2022)

Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia
por: Oishi, Kengo, et al.
Publicado: (2018)

Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
por: Yin, John, et al.
Publicado: (2017)

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases
por: Muneoka, Katsumasa, et al.
Publicado: (2017)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
por: Llorca, Pierre-Michel, et al.
Publicado: (2022)

PM429. Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment
por: Hashimoto, Takashi, et al.
Publicado: (2016)

S37. STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
por: Sonnenschein, Susan, et al.
Publicado: (2018)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
por: Sumi, Satoko, et al.
Publicado: (2022)

Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
por: Shiina, Akihiro, et al.
Publicado: (2015)

Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder
por: Tadokoro, Shigenori, et al.
Publicado: (2011)

Autistic traits and cognitive profiles of treatment-resistant schizophrenia()
por: Nakata, Yusuke, et al.
Publicado: (2020)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
por: Kelly, Deanna L, et al.
Publicado: (2013)

Limonene Inhibits Methamphetamine-Induced Sensitizations via the Regulation of Dopamine Receptor Supersensitivity
por: Gu, Sun Mi, et al.
Publicado: (2019)

Onset Pattern and Long-Term Prognosis in Schizophrenia: 10-Year Longitudinal Follow-Up Study
por: Kanahara, Nobuhisa, et al.
Publicado: (2013)

Active-State Model of a Dopamine D(2) Receptor - Gα(i) Complex Stabilized by Aripiprazole-Type Partial Agonists
por: Kling, Ralf C., et al.
Publicado: (2014)

Treatment of puberty trichotillomania with low-dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2015)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
por: Mohr, Pavel, et al.
Publicado: (2022)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
por: Lippi, Matteo, et al.
Publicado: (2022)

Supersensitive Kappa Opioid Receptors Promotes Ethanol Withdrawal-Related Behaviors and Reduce Dopamine Signaling in the Nucleus Accumbens
por: Rose, Jamie H., et al.
Publicado: (2015)

Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
por: Kesby, JP, et al.
Publicado: (2018)

Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models
por: Conn, Kyna-Anne, et al.
Publicado: (2020)

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_798fi7lhv0embuu8nmftf7hfkd